High-throughput flow cytometry compatible biosensor based on fluorogen activating protein technology

Cytometry Part A

Volumn 83 A, Issue 2, 2013, Pages 220-226

  Wu, Yang ^a   Tapia, Phillip H ^a   Fisher, Gregory W ^b   Waggoner, Alan S ^b   Jarvik, Jonathan ^b   Sklar, Larry A ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Flow cytometry; Fluorogen activating protein; High throughput; Live cell; Protein trafficking

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE RECEPTOR CCR5; FLUORESCENT DYE; FUCHSINE; HYBRID PROTEIN; ISOPRENALINE; MALACHITE GREEN; RANTES;

ARTICLE; BIOSYNTHESIS; CELL STRAIN U937; CHEMISTRY; DOSE RESPONSE; DRUG POTENTIATION; FLOW CYTOMETRY; GENETIC PROCEDURES; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; METHODOLOGY; PROTEIN BINDING;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BIOSENSING TECHNIQUES; CHEMOKINE CCL5; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; ISOPROTERENOL; PROTEIN BINDING; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, CCR5; RECOMBINANT FUSION PROTEINS; ROSANILINE DYES; U937 CELLS;

EID: 84873097681     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22242     Document Type: Article

References (23)

1. Overington JP, Al-Lazikani B, Hopkins AL. Opinion-How many drug targets are there? Nature Rev Drug Discov 2006; 5: 993-996.
2. Insel PA, Tang CM, Hahntow I, Michel MC. Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets. Biochim Biophys Acta-Biomembr 2007; 1768: 994-1005.
3. Gurevich VV, Gurevich EV. GPCR monomers and oligomers: It takes all kinds. Trends Neurosci 2008; 31: 74-81.
4. Munoz LM, Lucas P, Holgado BL, Barroso R, Vega B, Rodriguez-Frade JM, Mellado M. Receptor oligomerization: A pivotal mechanism for regulating chemokine function. Pharmacol Therap 2011; 131: 351-358.
5. Milligan G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol 2009; 158: 5-14.
6. Pepe S, van den Brink OWV, Lakatta EG, Xiao RP. Cross-talk of oploid peptide receptor and beta-adrenergic receptor signalling in the heart. Cardiovasc Res 2004; 63: 414-422.
7. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, Henegouwen P, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: Implications for cancer therapy. Curr Cancer Drug Targets 2009; 9: 748-760.
8. Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Frontiers Biosci Landmark 2008; 13: 1857-1865.
9. Wu Y, Tapia PH, Fisher GW, Simons PC, Strouse JJ, Foutz T, Waggoner AS, Jarvik JW, Sklar LA. Discovery of regulators of receptor internalization by high throughput flow cytometry. Mol Pharmacol 2012; 82: 645-657.
10. Szent-Gyorgyi C, Schmidt BA, Creeger Y, Fisher GW, Zakel KL, Adler S, Fitzpatrick JAJ, Woolford CA, Yan Q, Vasilev KV, Berget PB, Bruchez MP, Jarvik JW, Waggoner A. Fluorogen-activating single-chain antibodies for imaging cell surface proteins. Nature Biotechnol 2008; 26: 235-240.
11. Fisher GW, Adler SA, Fuhrman MH, Waggoner AS, Bruchez MP, Jarvik JW. Detection and quantification of beta 2AR internalization in living cells using FAP-based biosensor technology. J Biomol Screening 2010; 15: 703-709.
12. Lopalco L. CCR5: From natural resistance to a new Anti-HIV strategy. Viruses-Basel 2010; 2: 574-600.
13. Kahsai AW, Xiao KH, Rajagopal S, Ahn S, Shukla AK, Sun JP, Oas TG, Lefkowitz RJ. Multiple ligand-specific conformations of the beta(2)-adrenergic receptor. Nature Chem Biol 2011; 7: 692-700.
14. Jarvik JW, Fisher GW, Shi C, Hennen L, Hauser C, Adler S, Berget PB. In vivo functional proteomics: Mammalian genome annotation using CD-tagging. Biotechniques 2002; 33: 852-866.
15. Holleran J, Brown D, Fuhrman MH, Adler SA, Fisher GW, Jarvik JW. Fluorogen-activating proteins as biosensors of cell-surface proteins in living cells. Cytometry Part A 2010; 77A: 776-782.
16. http://www.mbic.cmu.edu/images/datasheet/MG-2p-NH2-info_rev21.pdf.
17. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes-Characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedebergs Arch Pharmacol 2004; 369: 151-159.
18. Venkatesan S, Rose JJ, Lodge R, Murphy PM, Foley JF. Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol Biol Cell 2003; 14: 3305-3324.
19. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TNC, Proudfoot AEI. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276: 276-279.
20. Napier C, Sale H, Mosley M, Rickett G, Dorr P, Mansfield R, Holbrook M. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol 2005; 71: 163-172.
21. Mueller A, Strange PG. Mechanisms of internalization and recycling of the chemokine receptor, CCR5. Eur J Biochem 2004; 271: 243-252.
22. Mack M, Cihak J, Simonis C, Luckow B, Proudfoot AEI, Plachy J, Bruhl H, Frink M, Anders HJ, Vielhauer V and others. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol 2001; 166: 4697-4704.
23. Ozhalici-Unal H, Pow CL, Marks SA, Jesper LD, Silva GL, Shank NI, Jones EW, Burnette JM, Iii, Berget PB, et al. A rainbow of fluoromodules: A promiscuous scFv protein binds to and activates a diverse set of fluorogenic cyanine dyes. J Am Chem Soc 2008; 130: 12620-12621.